Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expo East New Products In Brief

This article was originally published in The Tan Sheet

Executive Summary

Enzymedica launches enzyme/probiotic combo: Enzymedica Inc. launches Digest Gold + Probiotics, an enzyme/probiotic tandem, in the digestive product category at the Natural Products Expo East tradeshow in Boston Sept. 23. The combination product aims to give consumers more convenient and complete digestive care, a spokeswoman said. Additionally, Enzymedica's new TherActive delivery system helps the product's 500 million active probiotic cultures maintain stability on the shelf and in the intestinal tract, the Port Charlotte, Fla.-based firm claims. The delivery system releases enzymes into the upper section of the stomach while allowing the probiotic cultures to pass through the intestines before being released. Enzymedica maintains that a 30-day test showed TherActive products retain 100 percent of their "guaranteed potency" compared to 3 percent for "typical refrigerated probiotics." The product, which began shipping Sept. 1 and is available at Whole Foods and other chains, will be sold in 45- and 90-count bottles for suggested retail prices of $29.98 and $54.98, respectively, according to the spokeswoman

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS103432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel